Sustained Release Excipients Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Sustained Release Excipients Market is Segmented by Product Type (Gelatin, Polymers, Minerals, Sugars, and Other Product Types), Route of Administration (Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Other Routes of Administration), Technology (Targeted Delivery, Microencapsulation, Wurster Technique, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers values in USD million for all the above-mentioned segments.

Sustained Release Excipients Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Sustained Release Excipients Industry Overview

The global sustained release excipients market is competitive and consists of several major players. Mergers, acquisitions, collaborations for research and marketing, and the development of innovative products are some of the key strategies competitors are adopting to enhance their market share. Companies like Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd hold a substantial share in the market.

Sustained Release Excipients Market Leaders

  1. Mylan N.V.

  2. Pfizer, Inc.

  3. Sun Pharmaceutical Industries Ltd.

  4. Salix Pharmaceuticals

  5. Novartis AG

  6. *Disclaimer: Major Players sorted in no particular order
3.png

Sustained Release Excipients Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?